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Abstract
Objectives: We sought to determine if interleukin (IL)-1β and prostaglandin E2 (PGE2) 
(inflammatory mediators in pancreatic fluid) together with serum carbohydrate antigen (CA) 19–9 
could better predict intraductal papillary mucinous neoplasm (IPMN) dysplasia than individual 
biomarkers alone.
Methods: Pancreatic cyst fluid (n = 92) collected via endoscopy or surgery (2003–2016) was 
analyzed for PGE2 and IL-1β (Enzyme-Linked Immunosorbent Assay). Patients had surgical 
pathology-proven IPMN. Threshold values (PGE2 [>1100 pg/mL], IL-1β [>20 pg/mL], serum CA 
19–9 [>36 U/mL]) were determined.
Results: Levels of IL-1β were higher in high-grade (HGD)/Invasive-IPMN (n = 42) compared to 
Low/Moderate-IPMN (n = 37) (median [range], 54.6 [0–2671] vs 5.9 [0–797] pg/mL; P < 0.001; 
Area Under Curve [AUC], 0.766). Similarly, PGE2 was higher in HGD/Invasive-IPMN (n = 45) 
compared to Low/Moderate-IPMN (n = 47) (median [range], 1790 [20–15,180] vs. 140 [10–
14,630] pg/mL; P < 0.001; AUC, 0.748). Presence of elevated PGE2 and IL-1β (AUC, 0.789) 
provided 89% specificity and 82% positive predictive value (PPV) for HGD/Invasive-IPMN. 
Elevated levels of all three provided 100% Specificity and PPV for HGD/Invasive-IPMN.
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Conclusion: Cyst fluid PGE2, IL-1β, and serum CA 19–9 in combination optimize specificity 
and PPV for HGD/Invasive-IPMN and may help build a panel of markers to predict IPMN 
dysplasia.
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INTRODUCTION
Despite an increase in survival rates for other solid tumors, the prognosis for patients with 
pancreatic cancer remains poor. Pancreatic cancer is now the fourth leading cause of cancer-
related death in the United States and is predicted to become the second behind lung cancer 
by 2030.1,2 Although many cases of pancreatic cancer occur sporadically in the population, 
patients with pancreatic cysts are known to be at risk of developing pancreatic cancer.3 
Pancreatic cysts are being diagnosed more frequently due to the widespread use of high-
resolution imaging and increased physician awareness of symptoms associated with 
pancreatic cysts.4 In fact, pancreatic lesions are incidentally detected in up to 15% of 
American adults undergoing imaging for an unrelated reason.5–7
The most common type of mucinous pancreatic cyst is intraductal papillary mucinous 
neoplasm (IPMN), clinically noteworthy because it has significant potential to progress to 
invasive pancreatic cancer. Although the natural history of IPMN is not well understood, 
these precursor lesions are thought to progress in a stepwise fashion, thereby offering a 
window of opportunity to intervene prior to malignant transformation. While most IPMNs 
are low/moderate grade and can be safely monitored as low-risk, high grade (HGD) and 
invasive IPMN are high-risk for malignant transformation and should be resected in fit 
patients; however, accurate risk stratification is difficult to achieve pre-operatively. 
Determination of pancreatic duct involvement (main, branch, or mixed) by imaging or 
endoscopic ultrasound may identify higher risk main duct or mixed type cysts that are 
usually recommended for resection,8 but this alone is often not sufficient to make a 
definitive, accurate diagnosis of malignancy. Additionally, nearly 30% of IPMN are 
misclassified preoperatively as involving the main duct when compared to surgical 
pathology; conversely, 20% of IPMN thought to have branch-duct involvement alone have 
main duct-involvement on surgical pathology.9
To aid in the complex clinical management of IPMN, the International Consensus 
Guidelines were established in 200610 and subsequently revised in 2012.8 Based upon the 
assessment of clinical and radiological features, the consensus guidelines demonstrate high 
sensitivity (>90%) for predicting malignancy but very low specificity (25–30%).11–14 This 
low specificity results in potentially morbid pancreatic surgical resection (1–5% mortality, 
20–40% morbidity) of low-risk benign IPMN.15,16 The most recent 2016 revision to the 
guidelines states that elevated serum levels of the tumor marker carbohydrate antigen 19–9 
(CA 19–9 ≥37 U/mL) may be associated with high-risk IPMN, but use of this biomarker is 
limited by its low specificity and absence in some patients.17 To improve upon these existing 
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management algorithms, accurate and reliable biomarkers that correlate with malignant 
potential or dysplastic grade of IPMN are clearly needed.
Analysis of pancreatic cyst fluid, obtained during endoscopic ultrasound-guided needle 
aspiration, has gained recent favor to aid in differentiating low- from high-risk IPMN.18 
Although cyst fluid cytology may assist in diagnosing malignancy, it is often inaccurate or 
non-diagnostic for IPMN dysplasia. A few promising molecular markers (tumor/DNA) in 
cyst fluid have been identified and validated for clinical use, but to date none correlates with 
dysplasia or can predict the natural history of the cyst.18 A concerted research effort is 
ongoing to identify novel cyst fluid biomarkers with sufficient diagnostic utility. Reflecting 
the role of inflammation in malignancy, we previously discovered and validated that elevated 
levels of cyst fluid prostaglandin E2 (PGE2) correlated with IPMN dysplastic grade19,20; 
subsequently, another group provided evidence that the inflammatory cytokine 
interleukin-1β (IL-1β) was an accurate predictor of HGD/Invasive-IPMN.21
In the present study, we sought to externally validate IL-1β as an indicator of IPMN 
malignant risk in a larger group of patients. In addition, we evaluated the diagnostic 
performance of IL-1β, PGE2, and currently employed serum CA 19–9 in the same cohort, 
alone or in combination. We report that the novel combination of these cyst fluid and serum 
biomarkers is able to better predict high-risk disease warranting surgical resection, while 
distinguishing low-risk lesions that may safely undergo active surveillance.
MATERIALS AND METHODS
After informed consent was obtained, pancreatic cyst or duct fluid was gathered at the time 
of preoperative endoscopy (via endoscopic ultrasound guided fine-needle aspiration) or at 
the time of pancreatic resection (June 2003-August 2016). Aliquots were stored at −80°C 
and subsequently thawed on ice for biomarker testing. All patients underwent surgical 
resection with confirmed diagnosis of IPMN, using the World Health Organization criteria to 
determine dysplastic grade. Patients were divided into two groups based on dysplastic grade: 
the first group (low-risk IPMN) included those with Low or Moderate-grade IPMN, whereas 
the second group (high-risk IPMN) included those with HGD or Invasive IPMN.
Demographics and clinical data including preoperative serum CA 19–9 were supplemented 
through electronic medical record review. Pancreatitis and main pancreatic duct involvement 
were determined by surgical pathology. Patients using nonsteroidal anti-inflammatory drugs 
(NSAIDS) during their pre-operative evaluation were considered to be NSAID users. All 
data were gathered and stored in compliance with the Indiana University Institutional 
Review Board.
Biomarker Measurement and Analysis
Pancreatic fluid levels of IL-1β and PGE2 were measured using commercially available 
ELISA kits (Cat#DLB-50; R&D, Minneapolis, Minn and #RPN222; GE Healthcare Life 
Sciences, Pittsburgh, Penn). PGE2 data for patients included in the present study as well as 
determination of the optimal PGE2 threshold (>1100 pg/mL) have been published 
previously.20 The threshold value of IL-1β (>20 pg/mL) was approximated using Youden’s 
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Index to optimize sensitivity and specificity for high-risk lesions. The cutoff value for CA 
19–9 (>36 U/mL) was determined using our institution’s reported normal range.
Sensitivity (Sn), Specificity (Sp), Positive Predictive Value (PPV), Negative Predictive Value 
(NPV), and Accuracy (Acc) of individual biomarkers and combinations were calculated 
using these defined values. Biomarker levels were compared using the Wilcoxon rank-sum 
test and receiver operating characteristic (ROC) curve analysis. Descriptive statistics 
including mean, median, and frequencies were calculated as appropriate. Baseline group 
characteristics between low- and high-risk IPMN were compared using t-test for continuous 
data and chi-square for categorical data. Pearson correlation was used to determine 
associations between baseline characteristics and biomarker levels. Multivariable analysis 
was performed to determine if biomarkers were independent predictors of IPMN dysplastic 
grade. IBM SPSS Statistics for Windows, Version 24.0 (Armonk, NY) and R Statistical 
Software, Version 3.4.3 (R Foundation, Vienna, Austria) were used for these analyses.
RESULTS
A total of 92 patients undergoing care for IPMN at Indiana University Health-University 
Hospital provided informed consent for pancreatic fluid collection at the time of pre-
operative endoscopy (n = 23) or pancreatic resection (n = 69). All 92 patients underwent 
surgical resection with pathology-confirmed diagnosis of IPMN (47 Low/Moderate-Grade, 
28 High-Grade [HGD], 17 Invasive). Low-risk (Low/Moderate-Grade) and high-risk (HGD/
Invasive) groups were similar in age, sex, and pre-procedural NSAID use (Table 1). On 
surgical pathology, those with HGD/Invasive-IPMN had a higher incidence of pancreatitis 
(81.8% vs 63.0%; P = 0.047) as well as main pancreatic duct involvement (79.1% vs 44.4%; 
P = 0.001).
Pancreatic fluid levels of IL-1β were significantly higher in patients with HGD/Invasive-
IPMN (n = 42) compared to those with Low/Moderate-IPMN (n = 37) (median [range], 54.6 
[0–2671] vs. 5.9 [0–797] pg/mL; P < 0.001) (Fig. 1A). On ROC curve analysis, IL-1β 
provided an AUC of 0.766. Similarly, pancreatic fluid concentrations of PGE2 were 
significantly higher in patients with HGD/Invasive-IPMN (n = 45) compared with Low/
Moderate-IPMN (n = 47) (median [range], 1790 [20–15,180] pg/mL vs. 140 [10–14,630] 
pg/mL; P < 0.001), providing an AUC of 0.748 on ROC curve analysis (Fig. 1B). These two 
pancreatic fluid biomarkers outperformed the currently employed serum CA 19–9 biomarker 
(AUC, 0.617). Circulating levels of serum CA 19–9 were not significantly different between 
those with HGD/Invasive-IPMN (n = 42) and Low/Moderate-IPMN (n = 35) (median 
[range], 28.5 [1–11,755] U/mL vs. 14 [1–497] U/mL; P = 0.079) (Fig. 1C). Additionally, if 
Invasive-IPMN were excluded from analysis, levels of IL-1β as well as PGE2 but not CA 
19–9 were significantly higher in HGD-IPMN versus Low/Moderate-IPMN (P = 0.002, P < 
0.001, P = 0.909 respectively).
Individual biomarkers (IL-1β or PGE2) were assessed against each clinical variable (age, 
sex, pancreatitis, NSAID use, main-duct involvement) using Pearson correlation and no 
significant correlations were detected (P > 0.05). On binary logistic regression including 
IL-1β, PGE2, main-duct involvement and pancreatitis on surgical pathology, main-duct 
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involvement and PGE2 concentration remained independent predictors of HGD/Invasive-
IPMN. IL-1β approached significance as an independent predictor of HGD/Invasive-IPMN 
(P = 0.054).
Beyond individual biomarker performance, we explored whether combinations of IL-1β, 
PGE2, and serum CA 19–9 would further enhance our ability to distinguish between low- 
and high-risk lesions. The best two-biomarker model including IL-1β + PGE2 improved the 
AUC to 0.789 relative to each alone on ROC curve analysis. The three-biomarker model 
with the addition of serum CA 19–9 increased the AUC slightly to 0.791 (Fig. 2). These 
stepwise models for individual biomarkers and combinations with associated AUC values 
are summarized in Table 2.
Using our predetermined threshold values for PGE2 (>1100 pg/mL), IL-1β (>20 pg/mL), 
and serum CA 19–9 (>36 U/mL), predictive metrics (Sensitivity, Specificity, Accuracy, PPV, 
NPV) were calculated for the biomarkers alone or in various combinations (using AND/OR 
statements) as summarized in Table 3. Individually, elevated IL-1β performed better than 
PGE2, providing respective Sensitivity (64.3%, 60.0%), Specificity (83.8%, 78.7%), 
Accuracy (73.4%, 69.6%), PPV (81.8%, 73.0%) and NPV (67.4%, 67.3%) in predicting 
HGD/Invasive-IPMN. Elevation of either PGE2 OR IL-1β resulted in higher Sensitivity 
(80%), capturing more high-risk IPMNs than each considered alone; Accuracy (75%) and 
NPV improved (75%) while PPV (75%) and Specificity (69.2%) decreased slightly. 
Combining IL-1β AND PGE2 enhanced Specificity for HGD/Invasive-IPMN to 89.2%. 
Elevated serum CA 19–9 in the presence of either elevated IL-1β OR PGE2 further 
enhanced Specificity (96.7%) and PPV (92.9%) for high-risk disease. If the two biomarkers 
IL-1β AND CA 19–9 or all three biomarkers were elevated above the specified threshold 
values, Specificity and PPV reached 100.0% with 29 true negatives as well as 11 and 6 true 
positives, respectively for the two and three biomarkers. We also evaluated these metrics in 
the presence of elevated IL-1β OR PGE2 OR CA 19–9, and this model provided the highest 
Sensitivity (88.9%) and NPV (78.3%), with moderate accuracy (69.0%) for predicting high-
risk lesions.
DISCUSSION
Given the aggressive nature of pancreatic cancer once established, implementing early 
detection and prevention strategies in patients who are at risk of developing pancreatic 
cancer should be a high priority. One such group is patients with IPMN, a known 
radiographically detectable precursor to pancreatic cancer. Unfortunately, current diagnostic 
tools used to evaluate and manage IPMN, including radiologic imaging, endoscopic 
ultrasound, and cyst fluid analyses, are not satisfactory. Pre-operative risk stratification 
according to recommendations outlined in the International Consensus Guidelines may 
result in unnecessary major surgery for a benign lesion (overtreatment) or surveillance of a 
malignant lesion (undertreatment). The challenge is to strike a balance between timely 
resection of high-risk lesions and avoidance of potentially morbid surgery for those at low-
risk. In order to better predict risk of malignant transformation and optimize patient care, 
additional tools are needed to supplement the existing algorithms.
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There are important limitations to current cyst fluid and serum biomarkers for diagnostic 
testing. The tumor marker CA 19–19 identified in serum has some diagnostic utility in 
identifying malignancy but lacks sufficient specificity for routine diagnostic use and fails as 
a test in Lewis antigen-negative patients.22–24 In direct contact with cells lining the cyst, 
pancreatic cyst fluid may reflect malignant changes occurring in the lesion; specifically, 
clues to ongoing events may be revealed upon analysis of cyst fluid biochemical markers, 
DNA, and cytology.25 Cytology alone however is often unreliable.26 Carcinoembryonic 
antigen (CEA) has been extensively studied and can distinguish between mucinous and non-
mucinous cystic lesions (>192 ng/ml) but does not correlate with dysplasia.27–30 DNA 
mutations in KRAS and GNAS, although diagnostic for cyst type, also do not predict 
malignancy.29,31,32 Clearly, the search must continue for predictive biomarkers with 
sufficient sensitivity and specificity for clinical use.
We previously reported that PGE2 levels in pancreatic duct/cyst fluid are elevated in HGD/
Invasive-IPMN compared to Low/Moderate-IPMN and subsequently validated this finding 
in a larger group of patients.19,20 In the present study, we analyzed levels of pancreatic cyst 
fluid IL-1β in this same larger cohort and report that IL-1β has higher Sensitivity, 
Specificity, Accuracy, PPV, and NPV than PGE2 in predicting HGD/Invasive-IPMN. 
Moreover, IL-1β and PGE2 each individually outperformed serum CA 19–9 as single 
biomarkers. Despite using different methods of analysis (ELISA vs. ultrasensitive multiplex 
sandwich immunoassay) and different threshold values, the performance of IL-1β in our 
hands was similar to that reported by Maker et al,21 thus externally validating their study of 
40 IPMN patients. Respective PPVs for correctly identifying high-risk cysts were 81.8% 
(our study) and 71% (Maker et al), and respective NPVs for correctly identifying low-risk 
cysts were 67.4% and 75%.
The presence of either elevated IL-1β OR PGE2 optimizes Sensitivity and Accuracy, 
allowing for detection of the majority of HGD/Invasive-IPMN pre-operatively, and most 
frequently categorizes lesions into risk-categories correctly; the addition of CA 19–9 (any of 
the three) further enhanced Sensitivity. As the number of elevated biomarkers accumulate 
(PGE2, IL-1β, serum CA 19–9), Specificity and PPV for HGD/Invasive-IPMN increase as 
high as 100%, so that clinicians can be more certain of the presence of a high-risk lesion 
requiring resection. Thus, the novel approach of combining these cyst fluid and serum 
biomarkers may lead to a diagnostic panel that can predict pathology and more accurately 
direct individual patients to surgery for high-risk lesions versus surveillance for low-risk 
disease. For IPMN patients under surveillance, changes in biomarker levels in longitudinal 
samples collected from the same patient may potentially signal increasing dysplasia and thus 
risk.
We have shown that IL-1β and PGE2 are complementary in their ability to identify high-risk 
IPMN. As they are both inflammatory mediators, this suggests that inflammatory processes 
may be occurring within the pancreatic cyst. On the one hand, inflammation is known to 
play a role in promoting malignant progression; alternatively, tumor growth and 
development as well as ductal obstruction may result in inflammation. In either case, 
mediators would be released in association with malignancy as observed in the present 
study. Interestingly, interleukin-1® has been shown to induce cyclooxygenase-2 expression 
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and PGE2 secretion in human neuroblastoma cells as well as in human lung fibroblasts.33,34 
Taken together, this suggests that the IL-1β, PGE2, and cyclooxygenase-2, which we 
previously showed to be overexpressed in precursor lesions known as pancreatic 
intraepithelial neoplasias and pancreatic adenocarcinomas,35,36 may be coordinately up-
regulated during the malignant progression of IPMN. In support, in many but not all cases, 
IL-1β and PGE2 were both elevated in the same pancreatic fluid specimen. Pertinent to our 
study, four other inflammatory pancreatic cyst fluid markers (matrix metallopeptidase 9, 
cancer antigen 72–4, soluble FAS ligand, interleukin-4) were shown to be elevated in high-
risk IPMN and when incorporated into a clinical/radiographic nomogram, demonstrated 
enhanced predictive performance37; this group suggested that anti-inflammatory strategies 
should be considered to prevent the malignant progression of IPMN, an intervention also 
supported by our study.
Limitations of the present study are that all patients and pancreatic fluid samples originated 
from a single institution. Additionally, only patients who underwent surgical resection, and 
were therefore symptomatic and/or deemed high-risk, were selected for inclusion in order to 
correlate findings with surgical pathology. Therefore, our results may not be applicable to a 
more general population of IPMN patients under surveillance who would be candidates for 
this type of pre-operative diagnostic testing. Finally, larger multi-institution clinical 
validation studies using prospectively collected specimens must be performed to confirm the 
utility of these markers as diagnostic tools for management of IPMN.
CONCLUSION
In the present study, we externally validated pancreatic fluid IL-1β as an accurate predictor 
of IPMN dysplasia. Furthermore, combinations of IL-1β, pancreatic fluid PGE2, and serum 
CA 19–9 demonstrated improved ability to stratify risk by discriminating HGD/Invasive-
IPMN from Low/Moderate-IPMN. Pending further validation, these complementary 
biomarkers may be useful in a diagnostic panel to supplement current algorithms for the 
optimal preoperative management of IPMN.
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IPMN Intraductal Papillary Mucinous Neoplasm
IL-1β Interleukin-1β
PGE2 Prostaglandin E2
CA 19–9 Carbohydrate Antigen 19–9
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AUC Area Under the Curve
NSAIDS Nonsteroidal anti-inflammatory drugs
Sn Sensitivity
Sp Specificity
PPV Positive Predictive Value
NPV Negative Predictive Value
Acc Accuracy
ROC Receiver Operating Characteristic
CEA Carcinoembryonic antigen
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A, Pancreatic fluid IL-1β and IPMN dysplastic grade. The concentration of IL-1β in 
pancreatic cyst or duct fluid is plotted according to IPMN dysplastic grade. The red error 
bars represent median +/− interquartile range. The y-axis is discontinuous at 20 pg/mL. B, 
Pancreatic fluid PGE2 and IPMN dysplastic grade. The concentration of PGE2 in pancreatic 
cyst or duct fluid is plotted according to IPMN dysplastic grade. The red error bars represent 
median +/− interquartile range. The y-axis is discontinuous at 1100 pg/mL. C, Serum CA 
19–9 and IPMN dysplastic grade. The concentration of serum CA 19–9 is plotted according 
to IPMN dysplastic grade. The red error bars represent median +/− interquartile range. The 
y-axis is discontinuous at 50 U/mL.
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Receiver Operating Characteristic Curve for IL-1β, PGE2, CA 19–9 ROC curves of the three 
individual biomarkers or combination for predicting high-grade/invasive IPMN are 
presented.
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TABLE 1.
Demographic and Clinical Characteristics of Patients With IPMN, Indiana University Health University 
Hospital, 2003–2016
Characteristics Low/Moderate Grade IPMN High Grade/Invasive IPMN P
Age, n/mean (SD), y 47/68.2 (11.1) 45/66.6 (10.3) 0.466
Sex, n (%) 0.306
 Male 18 (38.3) 22 (48.9)
 Female 29 (61.7) 23 (51.1)
Sample collection method, n (%) 0.547
 Endoscopy 13 (27.7) 10 (22.2)
 Surgery 34 (72.3) 35 (77.8)
Pre-procedure NSAID use, n (%) 15 (31.9) 9 (20.0) 0.193
Pancreatitis, n (%) 29 (63.0) 36 (81.8) 0.047
Main-duct involvement, n (%) 20 (44.4) 34 (79.1) 0.001
Bold indicates statistical significance with P < 0.05
NSAID indicates nonsteroidal anti-inflammatory drugs
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TABLE 2.
Predictive Accuracy of Selected Biomarkers for High Grade/Invasive IPMN
Prediction Models N AUC
Model 1: IL-1β 79 0.766
Model 2: PGE2 92 0.748
Model 3: CA 19–9 77 0.617
Model 4: IL-1β + PGE2 79 0.789
Model 5: IL-1β + CA 19–9 69 0.758
Model 6: PGE2 + CA 19–9 77 0.769
Model 7: IL-1β + PGE2 + CA 19–9 69 0.791
IL-1β indicates interleukin-1β; PGE2, prostaglandin E2; CA 19–9, carbohydrate antigen 19–9; AUC, Area Under the Receiver Operating 
Characteristic Curve
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TABLE 3.
Summary of Predictive Metrics for Biomarkers, as Individual Components or in Combination
Sn, % Sp, % Acc, % PPV, % NPV, %
1 Biomarker
 IL-1β (>20 pg/mL) 64.3 83.8 73.4 81.8 67.4
 PGE2 (>1100 pg/mL) 60.0 78.7 69.6 73.0 67.3
 CA 19–9 (>36 U/mL) 40.5 71.4 54.5 63.0 50.0
 Exactly 1 positive (any 1 of the 3) 32.5 75.9 50.7 65.0 44.9
2 Biomarkers
 IL-1β or PGE2 80.0 69.2 75.0 75.0 75.0
 IL-1β or CA 19–9 76.7 52.9 66.2 67.3 64.3
 PGE2 or CA 19–9 80.0 52.5 67.1 65.5 70.0
 IL-1β and PGE2 42.9 89.2 64.6 81.8 57.9
 IL-1β and CA 19–9 27.5 100.0 58.0 100.0 50.0
 PGE2 and CA 19–9 19.0 97.1 54.5 88.9 50.0
 Exactly 2 positive (any 2 of the 3) 40.0 86.2 59.4 80.0 51.0
 (IL-1β or PGE2) and CA 19–9 31.0 96.7 58.3 92.9 50.0
3 Biomarkers
 IL-1β and PGE2 and CA 19–9 15.0 100.0 50.7 100.0 46.0
 IL-1β or PGE2 or CA 19–9 88.9 46.2 69.0 65.6 78.3
IL-1β indicates interleukin-1β; PGE2, prostaglandin E2; CA 19–9, carbohydrate antigen 19–9; Sn, Sensitivity; Sp, Specificity; Acc, Accuracy; 
PPV, Positive Predictive Value; NPV, Negative Predictive Value.
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